Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Prostaglandins 33 (1987), S. 51-60 
    ISSN: 0090-6980
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Medicine
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-0738
    Keywords: Cyclohexylamine ; Pharmacokinetics ; Pharmacodynamics ; Cyclamate ; Cyclohexylamin ; Pharmakokinetik ; Pharmakodynamik ; Cyclamat
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Cyclohexylamin — ein Stoffwechselprodukt des künstlichen Süßstoffes Cyclamat — wurde in Dosen von 2,5, 5 und 10 mg/kg KG oral an gesunde Versuchspersonen verabreicht. Die Plasmahalbwertszeit von CHA betrug 3,5 bis 4,8 Std, wobei eine deutliche Abhängigkeit der Halbwertszeit von der applizierten Dosis beobachtet werden konnte. 86 bis 95% der verabfolgten Dosis wurden innerhalb 48 Std als unverändertes CHA im Urin ausgeschieden. Da Cyclohexylamin mit einem pKa von 10.6 eine stark basische Substanz ist, ist die fast vollständige enterale Resorption, ermittelt über die cumulative Urinausscheidung, als unerwartet hoch anzusehen. CHA verursachte einen dosisabhängigen Blutdruckanstieg, wobei eine enge Beziehung zwischen Blutdruckanstieg und den Cyclohexylaminplasmaspiegeln aufgestellt werden konnte. Auf Grund dieser Blutspiegel-Wirkungskurve konnte gezeigt werden, daß für einen signifikanten Blutdruckanstieg der kritische Cyclohexylaminplasmaspiegel zwischen 0,7 bis 0,8 μg/ml liegt. 10 mg/kg K.G. Cyclohexylamin verursachten einen signifikanten Anstieg der unveresterten Plasma-Fettsäuren und der cumulativen Katecholaminausscheidung im Harn, wohingegen Dosen von 2,5 und 5 mg/kg ohne Effekt waren. Diese Ergebnisse zeigen, daß CHA ein indirektes Sympathikomimetikum ist, das allerdings wesentlich weniger wirksam ist als verwandte sympathikomimetische Substanzen.
    Notes: Abstract Cyclohexylamine (CHA) a possible metabolite of the artificial sweetener cyclamate was administered orally in doses of 2.5, 5 and 10 mg/kg b.w. to healthy volunteers. Plasma half lives of CHA ranged from 3.5 to 4.8 h showing a clear dose dependency. 86 to 95 % of the dose administered was excreted in the urine during 48 h as unchanged drug. Since CHA is a fairly strong base with a pKa of 10.6 the almost complete enteral absorption was rather unexpected. Cyclohexylamine caused a dose dependent rise in arterial blood pressure. A close correlation between plasma levels of CHA and increase of mean arterial blood pressure could be established. The analysis of this concentration response curve revealed that plasma levels of CHA of about 0.7 to 0.8 μg/ml are required in order to cause a significant increase in arterial blood pressure. A significant increase in plasma free fatty acids and cumulative urinary excretion of catecholamines was observed only after the administration of 10 mg/kg b.w. CHA. Our findings are consistent with cyclohexylamine being an indirect acting sympathomimetic amine which is some orders of magnitude less potent than related sympathomimetic substances.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 41 (1991), S. 99-103 
    ISSN: 1432-1041
    Keywords: Nitrendipine ; i.v. infusion ; serum concentrations ; haemodynamic effects ; protein binding ; healthy subjects ; polyethylene glycol ; ethanol
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The haemodynamic effects of an i.v. infusion of 2 mg nitrendipine have been studied in six healthy volunteers. Nitrendipine significantly decreased the systolic (−8.3%) diastolic (−19.9%) and mean arterial (−11.6%) blood pressures and the peripheral vascular resistance (−57.8%), and significantly increased leg blood flow (+128%). Stroke volume did not change. Due to the increase in heart rate (+28.5%), the cardiac output (2.8.2%) rose significantly. The haemodynamic effects were closely related to the serum nitrendipine concentration. The sigmoidal Emax-model was appropriate to describe the data. Pronounced interindividual differences in the serum nitrendipine concentrations required to elicit 50% of the maximum haemodynamic effect (EC50) were observed. The EC50 for the increase in leg blood flow ranged from 2.9 to 30.9 ng/ml and for the reduction in peripheral vascular resistance from 2.1 to 25.7 ng/ml. Interindividual differences in EC50 values were less pronounced if based on unbound serum nitrendipine levels. The fraction of nitrendipine not bound to serum proteins showed a three-fold difference between subjects, with free fractions ranging from 0.011 to 0.036. The unbound EC50 values for the increase in leg blood flow varied between 0.06 and 0.44 ng/ml and for the reduction in peripheral vascular resistance from 0.07 to 0.35 ng/ml. Based on the serum concentrations associated with comparable haemodynamic effects nitrendipine was at least three-times more potent than nifedipine.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...